Related by context. All words. (Click for frequent words.) 59 Evoltra ® 58 Initiate Clinical Trial 57 Aviptadil 57 Exherin TM 57 Soliris eculizumab 57 targeted radiotherapeutic 56 Trofex 56 recombinant biopharmaceutical 56 vaccine GRNVAC1 56 ThermoDox R 56 ATryn ® GTC recombinant 56 FOLOTYN ® 56 liver resection surgeries 56 Cotara R 56 Personalized Immunotherapy 56 Thelin tm 55 Panzem 55 Mepact 55 Files IND 55 Bendamustine 55 ospemifene 55 LHRH antagonist 55 Nimotuzumab anti 55 StemEx R 55 Behcet uveitis 55 Factor VIIa 55 Hsp# Inhibitor 55 SNT MC# 55 Archexin 55 Intravenous Human 55 Soliris TM eculizumab 54 clevudine 54 candidate REP# 54 ARRY # 54 potently inhibit 54 Initiates Enrollment 54 StaphVAX R 54 Panzem R 54 therapeutic peptide 54 PrevOnco ™ 54 SYCREST 54 Kit CD# positive 54 DOS# 54 Prodarsan R 54 AA amyloidosis 54 PREOS R 54 Raptiva R 54 Clevudine 54 selective immunoproteasome inhibitor 54 IAP inhibitor 54 oral prodrug 54 hoFH 54 GTC recombinant human 54 immunotherapeutic vaccine 54 candidates bavituximab 54 Onalta 54 Civacir 54 Nimotuzumab 53 MOVIPREP R 53 mertansine 53 Onconase 53 HDAC Inhibitor 53 acetonide FA 53 JAK2 Inhibitor 53 novel VDA molecule 53 Pirfenidone 53 TYZEKA 53 Cellegesic 53 AEG# 53 MOZOBIL 53 Aplidin 53 FRDA 53 Diamyd ® 53 Icatibant 53 Files Investigational 53 motexafin gadolinium Injection 53 drug GAP #B# 53 Allovectin 7 R 53 methylnaltrexone bromide 53 Orphan Drug status 53 DC Bead 53 PNP inhibitor 53 GTC recombinant form 53 mitogen activated ERK kinase 53 VALSTAR 53 tafamidis 53 Allovectin 7 53 Urokinase 53 Orphan Drug Status 53 pharmacological chaperone 53 histamine dihydrochloride 53 suppresses tumor 52 Loramyc R 52 anti botulism antibody 52 Prodarsan 52 apaziquone 52 AnGes 52 MCSP respectively 52 Actemra tocilizumab 52 cinacalcet HCl 52 Onalta ™ 52 refractory chronic lymphocytic 52 Phase III Pivotal 52 PrevOnco 52 Nabi HB Intravenous 52 Initiates Phase II 52 Enkephalin 52 molecular imaging radiopharmaceutical 52 TXA# [002] 52 TM pralatrexate injection 52 Solazed TM 52 RNAi therapeutic targeting 52 autologous cellular immunotherapy 52 cytotoxic therapies 52 rheumatoid arthritis psoriatic arthritis 52 Somatuline Depot 52 subcutaneous RELISTOR 52 MT#/MEDI-# 52 Curaxin 52 Nexavar ® 52 orphan designation 52 Tamibarotene 52 histone deacetylase HDAC inhibitor 52 multiple myeloma MM 52 R bendamustine hydrochloride 52 ENTEREG ® 52 Neo Kidney Augment 51 Orphan Drug designation 51 Prochymal TM 51 Troxatyl 51 Orphan Drug 51 PI3K/Akt pathway inhibitor 51 PRESEPT study 51 AAG geldanamycin analog 51 Onco TCS 51 potent activator 51 Xcytrin R 51 Friedreich Ataxia FRDA 51 initiated Phase Ib 51 lucinactant 51 Thrombin topical Recombinant 51 acyclovir Lauriad R 51 CEQ# 51 autologous peripheral 51 SparVax ™ 51 oncolytic virus therapy 51 Emezine 51 Fx #A 51 BEMA Fentanyl 51 TELINTRA 51 generation URAT1 inhibitor 51 LibiGel ® 51 opioid induced constipation OIC 51 ATL# [002] 51 Augment ™ 51 ATryn ® 51 ZEVALIN ® 51 ALN TTR 51 Anavex #-# 51 Proxinium TM 51 refractory Hodgkin 51 Entereg TM 51 Familial Adenomatous Polyposis FAP 51 Ceflatonin R 51 ALN TTR# 51 Arzerra ofatumumab 51 Nanobody 51 lymphoid malignancies 51 Iluvien ® 51 reslizumab 51 Cloretazine ® 51 QNEXA ® 50 Tectin TM 50 PD LID 50 Phase IIa Clinical Trial 50 OrCel ® 50 PREOS 50 SomatoKine 50 Zingo TM 50 Fodosine 50 Biologic License Application BLA 50 liposomal formulation 50 AP# [003] 50 Zavesca ® 50 Cleviprex TM clevidipine 50 anticancer compound 50 NanoTab 50 non alcoholic steatohepatitis 50 Tarsa Therapeutics 50 Raptiva ® 50 ABL inhibitor 50 Spiegelmer ® 50 Zalypsis 50 Alzhemed TM 50 IMiDs 50 include Phenoptin TM 50 Manja Bouman CEO 50 CVBT #B 50 ABRAXANE ® 50 Fast Track Designation 50 trastuzumab DM1 T DM1 50 Phase IIb clinical trials 50 SUTENT ® 50 nasal calcitonin product 50 MAGE A3 ASCI 50 Premarket Notification 50 hypoxia activated prodrug 50 ruxolitinib 50 SUVN 50 MIS# 50 Neovasc Reducer 50 Junovan TM 50 Somatuline R Autogel R 50 vapreotide acetate 50 CB2 selective receptor agonist 50 CCR9 antagonist 50 ATL# [001] 50 AQ4N 50 Bone Graft 50 MORAb 50 EVIZON TM 50 Application BLA 50 Lixivaptan 50 orally administered inhibitor 50 sarcoma melanoma 50 Elagolix 50 E1 INT TM 50 Fast Track Status 50 skeletal sarcomere activator 50 rALLy clinical trial 50 sorafenib tablets 50 teduglutide 50 eniluracil 50 Sanvar R 50 LymphoStat B belimumab 50 RhuDex ® 50 investigational humanized monoclonal antibody 50 Alvesco R 50 novel histone deacetylase 50 Voraxaze 50 ReN# stem cell 50 TKM ApoB 50 generation purine nucleoside 50 adecatumumab MT# 50 Qutenza TM 50 TKM PLK1 49 PANVAC VF 49 Cand5 49 Phenoptin 49 Empatic TM 49 THALOMID 49 Pivotal Phase III 49 Therapik R 49 recombinant human 49 subcutaneous formulation 49 radiation sensitizer 49 ADVEXIN p# therapy 49 tezampanel NGX# 49 amifampridine phosphate 49 Kuvan TM sapropterin 49 tiapamil 49 next generation URAT1 49 nicotinic alpha 7 49 Curaxin CBLC# 49 Orphan Drug designations 49 GED aPC 49 alvespimycin 49 huN# DM1 49 Staphylococcus aureus Polysaccharide Conjugate 49 oral deforolimus 49 RANK Ligand inhibitor 49 Hepatitis C HCV 49 ThermoDox ® 49 Prodarsan ® 49 refractory Hodgkin lymphoma 49 Cinryze ™ 49 Phase #b/#a clinical 49 PKC# 49 Aryplase 49 Silodosin 49 KNS # 49 VBLOC R 49 omacetaxine mepesuccinate 49 VitiGam 49 PLK1 SNALP 49 INSPIRE Trial Phase III 49 Loramyc ® 49 ALN PCS 49 registrational studies 49 ATPace TM 49 Opterone R 49 diagnostic molecular imaging 49 MEK inhibitor 49 AzaSite Plus 49 IMA# 49 huC# DM4 49 preclinical efficacy 49 Loramyc 49 CCR5 mAb 49 Marketing Authorisation Application 49 CD# CEA 49 ANAVEX #-# [001] 49 topical anti infective 49 IMiDs R 49 inhibits tumor 49 Generx ™ 49 Clinical Trial Application 49 Maribavir 49 SinuNase ™ 48 Zorbtive TM 48 oral methylnaltrexone 48 Clinical Trial 48 PDE4 inhibitor 48 topically administered 48 Protexia R 48 R#/MEM # 48 Tarvacin Anti Cancer 48 Ceflatonin ® 48 anti CD3 monoclonal 48 P#X# antagonist 48 Cethrin 48 Annamycin 48 TBC# 48 lintuzumab SGN 48 Camvia 48 anticancer agent 48 Dupuytren Contracture 48 Excellagen 48 Chaim Lebovits President 48 Orathecin 48 Protexia ® 48 apoptosis proteins 48 Augment TM 48 sNDAs 48 apoptosis inducer 48 DOR# 48 PHX# 48 IND submission 48 RAPTIVA 48 synthetic retinoid 48 OMNARIS HFA 48 MyVax R 48 Dalbavancin 48 TRISENOX ® 48 Surfaxin LS 48 TKM Ebola 48 Neo Urinary Conduit 48 Vicinium TM 48 Glybera R 48 multicenter Phase II 48 Rhucin R 48 drug conjugate 48 GLP1 INT TM 48 JAK2 inhibitor 48 cutaneous T 48 compound ISA# 48 Fibrillex TM 48 candidate Zenvia 48 gemcitabine Gemzar ® 48 STEDESA 48 HGS# 48 antibody MAb 48 Ceflatonin 48 ASONEP TM 48 candidate NGX 48 EVIZON TM squalamine lactate 48 Dr. Arndt Schottelius 48 Fentanyl Taifun 48 diarrhea predominant irritable 48 intranasal formulation 48 Stimuvax R 48 drug ISA# 48 PROGENSA R 48 pralatrexate injection folate analogue 48 CIP TRAMADOL ER 48 Acute Radiation Syndrome ARS 48 HepaGam B TM 48 TACI Ig 48 registrational 48 TSX YM AIM 48 Esbriet pirfenidone 48 VEGF Trap 48 Ceplene ® histamine dihydrochloride 48 ACV1 48 CRMD# 48 patient derived xenografts 48 Zelrix 48 Anidulafungin 48 Phase Ib II 48 PDX pralatrexate 48 TAXUS Element Stent System 48 personalized cellular immunotherapy 48 Bioral Amphotericin B 48 Golimumab 48 silodosin 47 balsalazide tablet 47 ELACYT 47 systemic anaplastic large 47 Phase IIa trials 47 XOMA 3AB 47 Omacetaxine 47 sumatriptan DosePro 47 LymphoStat B TM 47 leading oral taxane 47 Humanitarian Device Exemption 47 ROTATEQ 47 allosteric modulator NAM 47 Initiate Phase 47 Tarvacin TM 47 JOULFERON 47 PROVENGE ® 47 supplemental biologics 47 granted Ortec 47 GLP toxicology studies 47 angiogenic therapy 47 oncology indications 47 Marketing Authorization Application 47 non nucleoside inhibitor 47 Simulect 47 IAP inhibitors 47 Application MAA 47 Biopump 47 vinorelbine emulsion 47 Inc. AMEX YMI 47 Amigal TM 47 PF # [002] 47 Harry Palmin President 47 Onrigin 47 cell lymphoma CTCL 47 Serostim ® 47 Mycograb 47 lexidronam injection 47 Shigamabs ® 47 JZP 47 R alvimopan 47 CD# monoclonal antibody 47 phase Ib 47 iv peramivir 47 Linjeta TM 47 laninamivir 47 castrate resistant prostate cancer 47 Fentanyl TAIFUN R 47 psoriasis IBD 47 Urocidin 47 SonoLysis 47 Roche PEGASYS R 47 Resten NG 47 Thrombotic thromboembolic complications 47 investigational pan BCR 47 oral NKTR 47 Orphan Drug Designation 47 Fast Track designations 47 rusalatide acetate 47 Protectan CBLB# 47 JAK inhibitor 47 autologous cellular therapies 47 registrational trial 47 autologous cell 47 application sNDA 47 cells EPCs 47 VALSTAR R 47 ONCONASE 47 AZX# 47 product platforms AZX# 47 CIP Fenofibrate 47 BLA filing 47 Abstral 47 Diabetic Macular Edema 47 Phase lll 47 EV# vaccine 47 ILUVIEN ® 47 NEUMUNE 46 ApoB SNALP 46 Phase IIb Trial 46 ANTEGREN 46 RapidFire ® 46 methylnaltrexone 46 torezolid phosphate 46 hypoparathyroidism 46 PSN# [002] 46 Diabetic Macular Edema DME 46 catheter occlusion 46 cyclobenzaprine hydrochloride extended 46 opioid induced constipation 46 XL# anticancer compounds 46 selective A2A adenosine receptor 46 faropenem medoxomil 46 Phase #b/#a 46 angiotensin analog 46 cGMP manufacture 46 injectable formulation 46 Guanilib 46 highly purified pasteurized 46 rufinamide 46 trodusquemine MSI 46 Phase 2a clinical trials 46 Pruvel 46 REPEL CV 46 submit Biologics License 46 Genasense ® oblimersen 46 acyclovir Lauriad ® 46 OMAPRO ™ 46 jee OH' muh 46 Phase 1a clinical 46 GATTEX ® 46 New Drug IND 46 ELADUR ™ 46 Genasense ® 46 remove meningioma meh 46 Initiated Phase 46 brentuximab vedotin SGN 46 Oxycyte ® 46 Daclizumab 46 Phase IIb Clinical Trial 46 post herpetic neuralgia PHN 46 sulodexide 46 OTCBB HXBM developer 46 severe oral mucositis 46 DAVANAT R 46 potent nucleoside analogue 46 FACTIVE R gemifloxacin 46 NEUGENE R 46 Subpart E 46 multicenter Phase III 46 cannabinor 46 ATryn R 46 ophthalmic indications 46 intravenous acetaminophen 46 SURFAXIN 46 Lenocta 46 alogliptin 46 ONTAK 46 submitted Biologics License 46 compound COTI 46 Zenvia ™ 46 Hedgehog pathway inhibitor 46 Microcyn Technology 46 VEGFR2 inhibitor 46 Acute Myeloid Leukemia AML 46 Certolizumab pegol 46 JAK1 46 Increlex TM 46 maribavir 46 Biologic License Application 46 Prednisporin TM 46 taliglucerase alfa 46 Genasense R oblimersen 46 superior bioprocessing 46 PHASE III 46 forodesine 46 Flutiform ™ 46 Oracea TM 46 Marqibo 46 Nerve Targeting Drug 46 opioid induced bowel dysfunction 46 topically applied SEPA 46 HIV integrase inhibitor 46 Biological License Application 46 CIMZIA r 46 mGluR5 negative 45 Submits Investigational 45 Parkinson disease levodopa induced 45 mTOR inhibitor 45 Tarceva TM 45 ZALBIN 45 NTx TM -# 45 Xyfid TM 45 POSIDUR TM ELADUR TM 45 VBLOC vagal blocking 45 Topical Interferon Alpha 2b 45 Cannabinor 45 Cimzia TM 45 dermal patch 45 candidate XP# 45 refractory gout 45 cetrorelix pamoate 45 MGCD# [001] 45 LUVENIQ 45 Aurexis 45 forodesine HCl 45 overactive bladder AA# 45 Zenvia Phase III 45 factor TNF receptor 45 targeted biologic therapies 45 MEK inhibitor RDEA# 45 MONOVISC 45 treat opioid induced 45 EOquin 45 zolpidem tartrate sublingual tablet 45 Entereg R 45 IIa trial 45 Exalgo TM 45 investigational hepatitis C 45 investigational oral hepatitis C 45 selective androgen receptor modulator 45 Marketing Authorisation Application MAA 45 OTCBB PYTO 45 IPLEX 45 CF# [002] 45 Cardiac myosin activators 45 INCB# [001] 45 refractory APL 45 alvimopan 45 dose escalation Phase 45 Kamada AAT 45 Rhucin ® recombinant 45 EVIZON ™ 45 CG# [003] 45 URG# 45 BEMA TM Fentanyl 45 APEX PD 45 Shigamabs R 45 Sym# 45 HA viscosupplementation 45 Premarket Approval Application 45 oral proteasome inhibitor 45 non nucleoside HCV 45 Ofatumumab 45 OpenArray TM 45 CryoSeal FS System 45 Veronate 45 midstage trials 45 tamibarotene 45 thrombin component 45 severe hypercholesterolemia 45 AcryMed technologies 45 AeroLEF TM 45 Targeted Immunotherapy 45 BLA submission 45 containing granisetron 45 AcryMed Incorporated 45 CCR5 antagonist 45 KALBITOR ® 45 IND Investigational New 45 Restanza 45 virus HCV protease inhibitor 45 polyneuropathy HIV DSP 45 prokinetic agent 45 ORE# 45 MOR# 45 sodium Injection 45 Fortigel 45 Glybera 45 Sinofuan 45 delivers fluocinolone acetonide FA 45 humanized monoclonal antibody 45 SinuNase TM 45 RIGScan ™ 45 cutaneous T cell 45 samarium Sm 45 Dacogen injection 45 Australian Therapeutic Goods 45 Allovectin 7 ® 44 Neurodex TM 44 sterile lidocaine patch 44 rolling Biologics License 44 Healive TM 44 arsenic trioxide injection 44 Alpharadin 44 humanized anti 44 TKB# 44 granulated mesalamine 44 Phase IIa trial 44 Biologics License Application BLA 44 investigational hepatitis B 44 preclinical 44 octreotide implant 44 Phase IIIb clinical 44 novel mTOR inhibitor 44 opioid bowel dysfunction 44 candidate Trofex TM 44 pseudobulbar affect PBA 44 CORTOSS 44 NP2 Enkephalin 44 CDP# 44 OLpur TM H2H 44 inhaled liposomal ciprofloxacin 44 MAA submission 44 NEBIDO R 44 commercialize DAVANAT ® 44 memantine HCl 44 skeletal muscle contractility 44 LEVADEX TM 44 investigational antiplatelet agent 44 Silenor ® doxepin 44 Biologics License Application 44 Phase Ib clinical trials 44 Dacetuzumab 44 ONSOLIS TM 44 C1 inhibitor rhC1INH 44 vitro ADME 44 drug Mylotarg 44 HepeX B TM 44 voclosporin 44 DirectSelect TM 44 Aurora kinase inhibitor 44 painful diabetic neuropathy 44 Marketing Authorization Application MAA 44 human C1 inhibitor 44 Project QTDP program 44 Zenvia TM 44 delta opioid receptor 44 Ketotransdel 44 Locteron ® 44 orBec 44 Vion Pharmaceuticals 44 CBLB# 44 Homspera 44 BEMA ® 44 sapropterin dihydrochloride 44 phase Ib clinical 44 Crofelemer 44 PEG PAL 44 erlotinib Tarceva ® 44 Phase Ib IIa 44 Premarket Approval PMA 44 GALNS 44 Phase 2b trial 44 Investigational Device Exemption IDE 44 relapsed multiple myeloma 44 Synagis palivizumab 44 clofarabine 44 candidates Augment ™ 44 phase IIb study 44 fractionated radiotherapy 44 prGCD 44 Oxytrex TM 44 markets Gelclair R 43 RenaZorb TM 43 Junovan 43 Laquinimod 43 brivaracetam 43 Phase Ib study 43 PNT# 43 PXD# 43 confirmatory Phase III 43 omacetaxine 43 Solzira TM 43 FORTIS M trial 43 miconazole Lauriad R 43 Unifill TM syringe 43 sBLA 43 Combination antiretroviral therapy 43 Anturol TM 43 SparVax TM 43 supplemental Biologics License Application 43 post operative ileus 43 dose escalation clinical 43 spinal nonfusion 43 INDs 43 Augment Bone Graft 43 forodesine hydrochloride 43 CryoCor Cardiac Cryoablation System 43 generation PNP inhibitor 43 dependent kinase inhibitor 43 HCV polymerase inhibitor 43 Nasdaq DVAX 43 AMPAKINE CX# 43 Luveniq 43 COSIRA trial 43 Ophena TM 43 Nasdaq PPHM 43 Liposomal Grb 2 43 mesylate tablets 43 PROMUS Element Stent System 43 diabetic macular edema DME 43 Genasense oblimersen sodium Injection 43 NASDAQ OSIR 43 compound INCB# 43 L Annamycin 43 oral antiviral 43 PREGNANT Study 43 skeletal muscle troponin 43 Lenocta TM 43 Abiraterone acetate 43 COPREXA 43 FDA Approvable Letter 43 Biologics Licensing 43 Aloxi Injection 43 REMOXY R 43 NEBIDO 43 IIa clinical 43 Hepatitis C virus HCV 43 TELCYTA 43 mGluR2 positive 43 Begin squeezing 43 dextromethorphan quinidine 43 initiate Phase Ib 43 dasatinib Sprycel ® 43 transmucosal delivery system 43 Nasdaq HALO 43 topical non steroidal 43 phase IIb clinical 43 severe gastroparesis 43 HCV protease inhibitor 43 investigational 43 ALVESCO R 43 Acetavance TM 43 Phase Ib 43 Vilazodone 42 ISENTRESS raltegravir 42 dyskinesia PD LID 42 Frova ® 42 relapsing multiple sclerosis 42 Aerosurf 42 Injectable Bone Graft 42 spermatagonial stem cells 42 Purifine ® PLC 42 ganetespib 42 Augment Injectable 42 IMVAMUNE R 42 lenalidomide Revlimid R 42 human lactoferrin 42 Accelerating apoptosis may 42 carfilzomib 42 GENTAMICIN SURGICAL IMPLANT 42 compound PMX # 42 Rhucin 42 investigational compound 42 HCV NS5B polymerase 42 NASDAQ PSDV ASX 42 NM# [001] 42 Testosterone MDTS ® 42 preclinical toxicology 42 relapsed refractory multiple myeloma 42 Phase IIB 42 k premarket 42 Phase Ib clinical 42 CORLUX CORT # 42 ICA # 42 technologies coatings microparticles 42 orphan drug 42 investigational HCV polymerase 42 PRTX 42 mesylate tablets approved 42 NASDAQ CXSP announced 42 CORT # 42 CNW YM BioSciences 42 melanocortin receptor agonists 42 Consumer Borrowing Slows 42 Restanza TM 42 incyclinide 42 hematological malignancies 42 TRANSDUR Sufentanil 42 Phase III clinical trials 42 Provecta 42 gastrointestinal disorders characterized 42 Investigational 42 Phase III 42 Cimzia ® 42 ELND# 42 novel orally administered 42 By JAMAAL ABDUL 42 IND enabling 42 investigational drug 42 lead Aganocide compound 42 DAC HYP 42 TRACON Pharmaceuticals Inc. 42 Apricus Bio 42 Keppra ® levetiracetam 42 Eclectica TM 42 GLP toxicology 42 WX UK1 42 Nasdaq KERX 42 telomerase inhibition 41 ongoing Phase 1b 41 OTCQX QRXPY 41 OncoVEX GM CSF 41 Anthim 41 dihydrochloride Phase 3 41 MT# MEDI 41 investigational atypical antipsychotic 41 phase IIa 41 Phase III clinical 41 ARIKACE 41 stimulating unfertilized eggs 41 Investigational Device Exemption 41 orthodontic tooth 41 toggle DDR 41 Phase IIb III 41 Nasdaq MBRX announced 41 REGENERX BIOPHARMACEUTICALS INC. 41 VQD 41 Phase 2b clinical trials 41 microcirculatory improvement 41 Phase III confirmatory 41 SAPIEN XT 41 candidate brentuximab vedotin 41 Nasdaq PGNX today 41 Nasdaq VICL 41 NYSE Amex PTN 41 develop bioterrorism countermeasures 41 Fast Track designation 41 Alinia 41 ispinesib administered 41 inhaled antibiotic 41 % uracil topical 41 ADVANCE PD 41 TRANSDUR TM Sufentanil 41 NanoKnife IRE System 41 dalbavancin 41 exocrine pancreatic insufficiency EPI 41 QNEXA 41 IND CTA 41 Telavancin 41 South Tchibala 41 phase 2a 41 NasdaqGM NTEC today 41 Expression Genetics 41 Cinryze TM 41 diabetic peripheral neuropathic DPN 41 Anturol ® 41 Drug Submission 41 human monoclonal antibody 41 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 41 intravenous ghrelin agonist 41 oral ridaforolimus 41 vilazodone 41 REMOXY ® 41 Corlux 41 Inc. NASDAQ ANPI 41 dacetuzumab SGN 41 LOMUCIN TM 41 Inc. Nasdaq IDMI 41 breast irradiation APBI 41 Anturol 41 crofelemer 41 tezampanel 40 Cyclooxygenase Inhibiting Nitric Oxide 40 Fodosine TM 40 NASDAQ PGNX 40 Rhucin ® 40 tracer uptake 40 IL-#/# 40 New Drug Application 40 Phase IIb trials 40 Phase 2a clinical 40 oral nucleoside analogue 40 Teflaro 40 phase IIa clinical 40 Market Authorization Application 40 RSD# oral 40 relapsed MCL 40 placebo controlled Phase 40 Phase IIa clinical trials 40 Linjeta ™ 40 oxymorphone ER 40 Cinryze TM C1 inhibitor 40 Biologics License Applications 40 R roscovitine CDK cyclin 40 visilizumab 40 clinical trial 40 initiate Phase 1b 40 non constipation irritable 40 PRECISE Trial 40 Arikace 40 candidate WF# 40 lomitapide 40 pediatric glioma 40 #nm LL 40 Calmare pain 40 NGX# 40 NASDAQ IDEV 40 postherpetic neuralgia PHN 40 intravenous formulation 40 Drug Applications INDs 40 OROS R Hydromorphone 40 Nasdaq MBRX 40 AVAPRO R AVALIDE R 40 ecallantide 40 initiate Phase IIb 40 Nasdaq PCYC 40 Phase 2b clinical 40 Phase 2b 40 inhaled formulation 39 ofatumumab HuMax CD# 39 PMA submission 39 dose escalation trial 39 sNDA submission 39 eprodisate KIACTA TM 39 multicenter Phase 39 Nasdaq VNDA 39 Pharmion Corporation 39 MEND CABG II 39 FloTrac 39 Phase 1b clinical 39 MCOT TM 39 exploratory Phase IIa 39 pivotal bioequivalence 39 Phase IIb clinical 39 Phase IIa clinical 39 AEOL # 39 sNDA 39 Trizytek 39 arimoclomol 39 exome capture 39 Pharmos pipeline 39 Linaclotide 39 Phase II